



Introduction

Atopic dermatitis (AD) is a prevalent dermatological disease often beginning in childhood, manifesting with potentially severe symptoms. Beyond topical therapies, a range of systemic therapies with varying HTA outcomes and pricing structures are now available to appropriate patients in Germany. AD imposes in Germany and across Europe high direct and indirect costs, which have gained new dynamics through systemic therapies. This ongoing study aims to identify and analyze the actual care pathways and existing cost structures in AD therapy in Germany.

Method





Results: Current Healthcare



Results: Systemic Therapy of Atopic Dermatitis

		Biologicals ( Dupilumab / Tralokinumab )	JAK inhibitor ( Abrocitinib / Baricitinib / Upadacitinib )	Conventional ( Azathioprine / Ciclosporin / MTX )
Number of patients	Total N	2,786 (79.7%)	556 (15.9%)	653 (18.7%)
	Year 2020	761 (73.9%)	4 (0.4%)	318 (30.9%)
	Year 2023	2,216 (79.4%)	453 (16.2%)	257 (9.2%)
Completed Therapy	Ø Cost per patient	13,122 € (7,302€ - 24,652€)	9,488 € (4,299€ - 19,841€)	395 € (163€ - 830€)
	Ø Duration of therapy in quarters per patient	3 (2 - 6)	3 (1 - 5)	2 (1 - 4)
	% proportion of patients with a therapy duration of just one quarter	7.5%	12.4%	23.7%
% proportion of patients		59.5%	58.5%	20.8%
Permanent Therapy	Ø Costs per quarter per patient	4,645 € (4,528€ - 4,645€)	5,141 € (3,153€ - 5,725€)	300 € (163€ - 523€)
	Year 2020	4,337 € (3,990€ - 4,337€)	4,043 € (3,714€ - 4,741€)	202 € (96€ - 278€)
	Year 2023			
Systemic Therapy gap *	Total N	254 (9.1%)	33 (5.9%)	177 (27.1%)
	Ø Duration in quarters	9 (6 - 12)	6 (5 - 7)	12 (9 - 13)
Ø Duration between diagnosis and start of therapy in quarters		4 (1 - 9)	7 (5 - 10)	3 (1 - 7)

\* no medication for at least 4 quarters



Discussion

- The results show a significant change in the application and duration of systemic therapies for AD patients over the past few years, leading to considerable economic impacts in Germany. In particular, the higher prices of Biologicals and JAK inhibitors, combined with a significantly longer treatment duration, are the main contributing factors.
- One in five conventional patients receives long-term therapy, which resulted in a significant cost saving of approximately €16,540 per patient in 2023 compared to biologic therapy. From an economic perspective, conventional therapy should be preferred as the first-line therapy in new patients, if medically appropriate.
- Understanding actual treatment pathways from real-world data in a healthcare system without formal reimbursement restrictions can help identify medically and economically meaningful treatment pathways and sequences.